EIC funding to develop SN132D - the first selective contrast agent for MRI diagnostics of endometriosis

3M kr SEK

Funder	Vinnova
Recipient Organization	Spago Nanomedical Ab (Publ)
Country	Sweden
Start Date	Jan 01, 2024
End Date	Jun 30, 2024
Duration	181 days
Number of Grantees	1
Roles	Principal Investigator
Data Source	Swedish Research Council
Grant ID	`2023-03784_Vinnova`

Grant Description

Purpose and goal:

The project aim was to prepare a competitive proposal for EIC Accelerator, including market analysis, application texts, financial model and mandatory appendices, such as pitch deck and annex. During the course of the project, we have prepared and submitted a stage 1 and a full stage 2 proposal to EIC Accelerator.

Expected results and effects:

The project aim has been fulfilled as we completed the preparations that were planned and submitted a stage 1 and step 2 application. Approach and implementation:

During the preparation phase, we have carried out a detailed market analysis, drawn up a regulatory plan and created and submitted proposal to EIC Accelerator. The project has been carried out according to plan.